Latest & greatest articles for aspirin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on aspirin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on aspirin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Aspirin

Acetylsalicylic acid (ASA) more commonly known as aspirin is a painkiller that has a wide range of uses. It is frequently used to treat fever, mild pain, tooth aches, headaches and muscle aches. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) and can be used in the management of conditions such as heart attack, arthritis, blood clots and stroke. Aspirin, has been used for thousands of years, initially extracted from the leaves of willow trees.

Aspirin works in much the same way as other NSAIDs but has additional properties, such as antiplatelet activity which can make it additionally useful. More recently aspirin has been linked with cancer prevention. But the potential benefits of aspirin need to be weighed against the potential side effects, which includes gastrointestinal bleeding and Reye’s syndrome. It should be noted that aspirin should not be used in people who are allergic to drugs such as ibuprofen or a more generalized intolerance to NSAIDs. It should also be used cautiously in asthmatics and/or those with bronchospasm associated with NSAID use.

Research evidence, clinical trials and guidelines on Aspirin

The Trip Database has an extensive collection of articles on aspirin ranging from clinical trials, systematic reviews, clinical guidelines and case reports. These can be found via searching the site.

Top results for aspirin

181. Low-dose aspirin at ≤16 weeks of gestation for preventing preeclampsia and its maternal and neonatal adverse outcomes: A systematic review and meta-analysis (Full text)

Low-dose aspirin at ≤16 weeks of gestation for preventing preeclampsia and its maternal and neonatal adverse outcomes: A systematic review and meta-analysis The aim of the present meta-analysis study was to evaluate the efficacy of low-dose aspirin, commenced at ≤16 weeks of gestation, in preventing preterm and term preeclampsia, as well as associated maternal and neonatal adverse events in women at risk of preeclampsia. The Embase, PubMed, Cochrane Central Register of Controlled Trials (...) outcomes, including intrauterine growth retardation (IUGR) or small for gestation age infant (SGA), stillbirth or death, and newborn weight. A total of 10 RCTs involving 3,168 participants were included. The meta-analysis demonstrated that, compared with placebo or no treatment, low-dose aspirin was associated with a significant reduction in the overall risk ratio (RR) of preeclampsia regardless of the time to delivery [RR=0.67; 95% confidence interval (CI)=0.57-0.80]. This was apparent for preterm

2018 Experimental and therapeutic medicine PubMed abstract

182. Perioperative aspirin therapy in non-cardiac surgery: A systematic review and meta-analysis of randomized controlled trials. (Abstract)

Perioperative aspirin therapy in non-cardiac surgery: A systematic review and meta-analysis of randomized controlled trials. 29544957 2018 10 25 2018 12 02 1874-1754 258 2018 05 01 International journal of cardiology Int. J. Cardiol. Perioperative aspirin therapy in non-cardiac surgery: A systematic review and meta-analysis of randomized controlled trials. 59-67 S0167-5273(17)34953-7 10.1016/j.ijcard.2017.12.088 Wolff Georg G Department of Internal Medicine, Division of Cardiology, Pulmonology (...) of Cardiology, Pulmonology and Vascular Medicine, Heinrich-Heine-University, Düsseldorf, Germany; Systematic Investigation and Research on Interventions and Outcomes (SIRIO)-Medicine Research Network. eng Journal Article Meta-Analysis Review Systematic Review Netherlands Int J Cardiol 8200291 0167-5273 0 Platelet Aggregation Inhibitors R16CO5Y76E Aspirin IM Int J Cardiol. 2018 May 1;258:74-75 29544959 Aspirin administration & dosage adverse effects Cardiovascular Diseases mortality surgery Hemorrhage

2018 International journal of cardiology

183. Continued versus interrupted aspirin use and bleeding risk after endoscopic submucosal dissection of gastric neoplasms: a meta-analysis (Full text)

Continued versus interrupted aspirin use and bleeding risk after endoscopic submucosal dissection of gastric neoplasms: a meta-analysis Balancing the risk of bleeding and thromboembolic events for patients who use aspirin and need to undergo endoscopic submucosal dissection (ESD) for gastric neoplasms is a delicate process. The current guidelines from different associations provide inconsistent recommendations.MEDLINE and EMBASE databases were searched through August 2017 for studies (...) that compared the risk of post-ESD bleeding in patients who continued aspirin vs. those who discontinued aspirin preoperatively. Pooled odds ratios (OR) and 95% confidence intervals (CI) were calculated using a random-effect model, generic inverse variance method. The between-study heterogeneity was quantified using the Q statistic and I2 .A total of five studies that included 700 patients were identified. Our meta-analysis could not demonstrate a significantly increased risk of post-ESD bleeding among

2018 Annals of Gastroenterology PubMed abstract

184. Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies. (Full text)

Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies. Epidemiological studies have clarified the potential associations between regular aspirin use and cancers. However, it remains controversial on whether aspirin use decreases the risk of cancers risks. Therefore, we conducted an updated meta-analysis to assess the associations between aspirin use and cancers.The PubMed, Embase, and Web of Science databases were systematically searched up to March (...) 2017 to identify relevant studies. Relative risks (RRs) with 95% confidence intervals (CIs) were used to assess the strength of associations.A total of 218 studies with 309 reports were eligible for this meta-analysis. Aspirin use was associated with a significant decrease in the risk of overall cancer (RR = 0.89, 95% CI: 0.87-0.91), and gastric (RR = 0.75, 95% CI: 0.65-0.86), esophageal (RR = 0.75, 95% CI: 0.62-0.89), colorectal (RR = 0.79, 95% CI: 0.74-0.85), pancreatic (RR = 0.80, 95% CI: 0.68

2018 BMC Cancer PubMed abstract

185. Aspirin plus dipyridamole has the highest surface under the cumulative ranking curves (SUCRA) values in terms of mortality, intracranial hemorrhage, and adverse event rate among 7 drug therapies in the treatment of cerebral infarction. (Full text)

Aspirin plus dipyridamole has the highest surface under the cumulative ranking curves (SUCRA) values in terms of mortality, intracranial hemorrhage, and adverse event rate among 7 drug therapies in the treatment of cerebral infarction. The standardization for the clinical use of drug therapy for cerebral infarction (CI) has not yet determined in some aspects. In this paper, we discussed the efficacies of different drug therapies (aspirin, aspirin plus dipyridamole, aspirin plus clopidogrel (...) , aspirin plus warfarin, cilostazol, warfarin, and ticlopidine) for CI.We searched databases of PubMed and Cochrane Library from the inception to April, 2017, randomized controlled trials (RCTs) met the inclusion and exclusion criteria were enrolled in this study. The network meta-analysis integrated evidences of direct and indirect comparisons to assess odd ratios (OR) and surface under the cumulative ranking curves (SUCRA) value.Thirteen eligible RCTs including 7 drug therapies were included

2018 Medicine PubMed abstract

186. Arthroscopic bone graft procedure combined with arthroscopic subscapularis augmentation (ASA) for recurrent anterior instability with glenoid bone defect: a cadaver study (Full text)

Arthroscopic bone graft procedure combined with arthroscopic subscapularis augmentation (ASA) for recurrent anterior instability with glenoid bone defect: a cadaver study Glenoid bone loss and capsular deficiency represent critical points of arthroscopic Bankart repair failures. The purpose of this study was to evaluate an all-arthroscopic bone block procedure associated with arthroscopic subscapularis augmentation (ASA) for treating gleno-humeral instability with glenoid bone loss (GBL (...) . No lesions of the surrounding neurovascular structures were observed. No interference was found between the two bone block tunnels and the anchor tunnel used for the tenodesis.This study demonstrated the feasibility and reproducibility of this combined arthroscopic technique (bone block associated with ASA) in the treatment of anterior shoulder instability associated with anterior bone loss and anterior capsular deficiency.

2018 Journal of experimental orthopaedics PubMed abstract

187. Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty. (Full text)

Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty. Clinical trials and meta-analyses have suggested that aspirin may be effective for the prevention of venous thromboembolism (proximal deep-vein thrombosis or pulmonary embolism) after total hip or total knee arthroplasty, but comparisons with direct oral anticoagulants are lacking for prophylaxis beyond hospital discharge.We performed a multicenter, double-blind, randomized, controlled trial involving patients who were (...) undergoing total hip or knee arthroplasty. All the patients received once-daily oral rivaroxaban (10 mg) until postoperative day 5 and then were randomly assigned to continue rivaroxaban or switch to aspirin (81 mg daily) for an additional 9 days after total knee arthroplasty or for 30 days after total hip arthroplasty. Patients were followed for 90 days for symptomatic venous thromboembolism (the primary effectiveness outcome) and bleeding complications, including major or clinically relevant nonmajor

2018 NEJM Controlled trial quality: predicted high PubMed abstract

188. [The Role of Aspirin in Preeclampsia Prevention: State of the Art]. (Abstract)

[The Role of Aspirin in Preeclampsia Prevention: State of the Art]. The role of acetyl salicylic acid (ASA or aspirin) in preeclampsia prevention and in other complications has been subject to studies and controversies for the last 30 years. The first research results concerning the role of placenta in preeclampsia have been published by the end of seventies and they showed an increase in the platelet activity and a prostaglandin synthesis disturbance, as a consequence of a deficient (...) placentation. In the last twenty years of the XX century important studies were published on the aspirinprophylactic role in preeclampsia risk reduction.To analyze published studies about Aspirin use for preeclampsia prevention and about the more adequate dosage to be administered, Medline was used for searching the most relevant prospective research papers on this subject in order to evaluate current evidence about the use of aspirin in this context. Relevant citations were extracted from Embase, PubMed

2018 Acta medica portuguesa

189. CRACKCast Episode 149 – Aspirin and Nonsteroidal Agents

ingestion. Rosen’s In Perspective Aspirin, or acetylsalicylic acid, is widely consumed for its analgesic, anti-inflammatory, and antiplatelet effects… however salicylate toxicity is not a benign condition and causes a complex set of life-threatening metabolic derangements with significant morbidity and mortality. 20-30 people die every year from ASA overdoses. The very young and very old are at particular risk! It’s not just ASA that we worry about: other potential sources of salicylate toxicity include (...) ; Topical salicylates Oil of wintergreen Willow bark Bismuth subsalicylate ***Ingestion of oil of wintergreen is of particular concern given that 1 mL of 98% solution contains the equivalent salicylate of 1.4 grams of aspirin (this is one of those “one sip can kill” drugs).*** Core questions [1] What is the pathophysiology of ASA toxicity? Unpredictable GI absorption (2-4 hours, but can be longer – up to 12 hours) In the intestinal wall, liver, and red blood cells, aspirin is hydrolyzed to free

2018 CandiEM

190. The use of preoperative aspirin in cardiac surgery: A systematic review and meta-analysis. (Abstract)

The use of preoperative aspirin in cardiac surgery: A systematic review and meta-analysis. Despite the fact that aspirin is of benefit to patients following coronary artery bypass grafting (CABG), continuation or administration of preoperative aspirin before CABG or any cardiac surgical procedure remains controversial. Therefore, we performed a systematic review and meta-analysis to assess the influence of preoperative aspirin administration on patients undergoing cardiac surgery.Medline (...) database was searched using OVID SP interface. Similar searches were performed separately in EMBASE, PubMed, and Cochrane Central Registry of Controlled Trials.Twelve randomized controlled trials and 28 observational studies met our inclusion criteria and were included in the meta-analysis. The use of preoperative aspirin in patients undergoing CABG at any dose is associated with reduced early mortality as well as a reduced incidence of postoperative acute kidney injury (AKI). Low-dose aspirin (≤160 mg

2018 Journal of cardiac surgery

191. Population-wide Impact of Long-term Use of Aspirin and the Risk for Cancer. (Full text)

Population-wide Impact of Long-term Use of Aspirin and the Risk for Cancer. The US Preventive Services Task Force recently recommended the use of aspirin to prevent colorectal cancer and cardiovascular disease among many US adults. However, the association of aspirin use with the risk for other cancer types and the potential population-wide effect of aspirin use on cancer, particularly within the context of screening, remain uncertain.To examine the potential benefits of aspirin use for overall (...) and subtype-specific cancer prevention at a range of doses and durations of use and to estimate the absolute benefit of aspirin in the context of screening.Two large US prospective cohort studies, the Nurses' Health Study (1980-2010) and Health Professionals Follow-up Study (1986-2012), followed up 135 965 health care professionals (88 084 women and 47 881 men, respectively) who reported on aspirin use biennially. The women were aged 30 to 55 years at enrollment in 1976; the men, aged 40 to 75 years

2018 JAMA oncology PubMed abstract

192. Effect of low dose aspirin and dipyridamole on primary patency of arteriovenous grafts in hemodialysis patients: a randomized double-blind placebo-controlled trial (Full text)

Effect of low dose aspirin and dipyridamole on primary patency of arteriovenous grafts in hemodialysis patients: a randomized double-blind placebo-controlled trial There is some evidence for the efficacy of antiplatelet therapies in increasing the vascular access patency duration or decreasing the thrombosis of arteriovenous grafts.To determine the effect of low dose aspirin and dipyridamole on primary patency of arteriovenous grafts in hemodialysis patients.This randomized, double-blind (...) , placebo-controlled trial was done at Imam Reza Hospital in Mashhad, Iran from September 10, 2015 to July 05, 2016. Sixty hemodialysis patients, after the placement of a new arteriovenous graft, were divided into three study groups which including; Group 1, who received 80 mg aspirin tablet daily, Group 2 received 80 mg aspirin plus 75 mg dipyridamole daily and Group 3 received placebo daily. Primary unassisted patency was recorded in follow-up until 12 months and the outcomes were analysed using one

2018 Electronic physician Controlled trial quality: predicted high PubMed abstract

193. Aspirin therapy discontinuation and intraoperative blood loss in spinal surgery: a systematic review. (Abstract)

Aspirin therapy discontinuation and intraoperative blood loss in spinal surgery: a systematic review. The purpose of this study was to determine the effect of aspirin therapy discontinuation on intraoperative blood loss in spinal surgery. We searched Medline and Google Scholar 1946 to January 2017 inclusive for case-control studies, cohort studies, and controlled trials reporting intraoperative blood loss during spinal surgery in patients on pre-operative aspirin. Other outcome measures (...) reported in the eligible studies were collected as secondary outcomes. Two reviewers independently screened and extracted data from each study. Five retrospective cohort and two case-control studies were eligible for inclusion. Of the 1173 patients identified, 587 patients were never on aspirin (Ax), 416 patients had aspirin discontinued before surgery (Ad), ranging from 3 to 10 days, and 170 patients had aspirin continued until surgery (Ac). Six out of seven studies reported no statistically

2018 Neurosurgical review

194. Risk of complications with use of aspirin during renal biopsy: A systematic review. (Abstract)

Risk of complications with use of aspirin during renal biopsy: A systematic review. Bleeding is a well-known complication of percutaneous renal biopsy (PRB). Thus, antiplatelet agents are routinely held for most patients undergoing elective PRB to decrease bleeding risk.In this systematic review, we examine the association between antiplatelet use and bleeding during PRB. MEDLINE and EMBASE were searched from inception to December 2016 using terms that included "renal biopsy", "antiplatelet (...) ","aspirin", and "bleeding". Guidelines and systematic reviews were identified primarily through large databases, including the National Guideline Clearinghouse and Cochrane Database of Systematic Reviews. Two authors independently screened the results, and appraised and graded the evidence using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach.Out of 371 guidelines, 40 systematic reviews, and 709 primary studies originally identified, 4 guidelines, 1 systematic

2018 Clinical nephrology

195. Aspirin or heparin or both in the treatment of recurrent spontaneous abortion in women with antiphospholipid antibody syndrome: a meta-analysis of randomized controlled trials. (Abstract)

Aspirin or heparin or both in the treatment of recurrent spontaneous abortion in women with antiphospholipid antibody syndrome: a meta-analysis of randomized controlled trials. This study was designed to evaluate the efficacy of aspirin or heparin or both in the treatment for recurrent spontaneous abortion (RSA) in women with antiphospholipid antibody syndrome (APS).Systematic searches for randomized clinical trials (RCTs) evaluating on live birth and preterm delivery, preeclampsia (...) , intrauterine growth restriction, gestational diabetes, bleeding of RSA with APS patients receiving aspirin, and heparin therapy were carried out, from PubMed, EMBASE, ScienceDirect, and CNKI. Related data were extracted from eligible studies and then subjected to Reviewer Manage 5.3 for analysis. Relative risk (RR) and its 95% confidence interval were calculated.Nineteen publications with randomized controlled trials were selected for this study, which included a total of 1251 pregnant patients

2018 The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians

196. A Systematic Review on the Use of Aspirin in the Prevention of Deep Vein Thrombosis in Major Elective Lower Limb Orthopedic Surgery: An Update from the Past 3 Years. (Full text)

A Systematic Review on the Use of Aspirin in the Prevention of Deep Vein Thrombosis in Major Elective Lower Limb Orthopedic Surgery: An Update from the Past 3 Years. Introduction  Currently there are no consensuses in the national guidance on thromboprophylaxis following major elective lower limb surgery. Emerging clinical evidence suggests that aspirin could be just as effective as anticoagulants with a lower cost. The aim of this study was to provide an update based on literature of the past (...) 3 years for the use of aspirin as thromboprophylaxis after knee and hip arthroplasty. Materials and Methods  MEDLINE/EMBASE search was performed with appropriate terms for original articles from 2014 to 2017. Results  Eight articles were found. Five articles concluded that aspirin was an effective prophylactic. The collation of results on the deep vein thrombosis rate involved 43,012 patients who were prescribed aspirin, of which 283 (0.66%) suffered from symptomatic deep vein thromboses

2018 Surgery journal (New York, N.Y.) PubMed abstract

197. Maternal and child health: Associations between the timing and dosing of aspirin prophylaxis and term and preterm pre-eclampsia

Maternal and child health: Associations between the timing and dosing of aspirin prophylaxis and term and preterm pre-eclampsia Associations between the timing and dosing of aspirin prophylaxis and term and preterm pre-eclampsia | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Associations between the timing and dosing of aspirin prophylaxis and term and preterm pre-eclampsia Article Text Commentary Maternal and child health Associations

2018 Evidence-Based Medicine

198. Primary care: Rivaroxaban plus aspirin, compared with aspirin alone, reduced cardiovascular events in patients with stable peripheral or carotid artery disease, but increased the risk of major bleeding (Full text)

Primary care: Rivaroxaban plus aspirin, compared with aspirin alone, reduced cardiovascular events in patients with stable peripheral or carotid artery disease, but increased the risk of major bleeding Rivaroxaban plus aspirin, compared with aspirin alone, reduced cardiovascular events in patients with stable peripheral or carotid artery disease, but increased the risk of major bleeding | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising (...) Rivaroxaban plus aspirin, compared with aspirin alone, reduced cardiovascular events in patients with stable peripheral or carotid artery disease, but increased the risk of major bleeding Article Text Commentary Primary care Rivaroxaban plus aspirin, compared with aspirin alone, reduced cardiovascular events in patients with stable peripheral or carotid artery disease, but increased the risk of major bleeding Jonathan Mant Statistics from Altmetric.com Commentary on: Anand SS, Bosch J, Eikelboom JW, et al

2018 Evidence-Based Medicine PubMed abstract

199. Aspirin versus placebo in pregnancies at high risk for preterm pre-eclampsia. (Full text)

Aspirin versus placebo in pregnancies at high risk for preterm pre-eclampsia. A recent multicentre placebo-controlled trial by Rolnick et al. has indicated that taking 150 mg aspirin daily in women at high risk of pre-eclampsia reduced the incidence of the disease from 4.3% to 1.5% in comparison with placebo. Although the findings of this study are important, a high proportion of women withdrew their consent and not all safety outcomes have been reported. This journal watch article discusses

2018 Obstetric medicine Controlled trial quality: uncertain PubMed abstract

200. Combined Argon Laser and Low Dose Acetylsalicylic acid in Treatment of Acute Central Serous Chorioretinopathy. (Abstract)

Combined Argon Laser and Low Dose Acetylsalicylic acid in Treatment of Acute Central Serous Chorioretinopathy. This study was designed to evaluate the efficacy of low-dose of oral acetylsalicylic acid (aspirin) with focal argon laser for the treatment of acute central serous chorioretinopathy (CSCR). In this prospective case-control study, 40 Patients with acute CSCR were classified randomly to two groups; group A with no treatment as the control group and group B with argon Laser in focal (...) treatment once, followed by aspirin, 100 mg per day orally, with follow up period of 12 months by evaluation of visual acuity, and by Optical Coherence Tomography (OCT), every three months for one year. Patients in the second group treated with argon Laser and aspirin showed more clinically significant improvement in both visual acuity and OCT macular thickness by the end of the follow-up period when compared with the observational group. It was concluded that argon Laser with low-dose oral aspirin

2018 Medical hypothesis, discovery & innovation ophthalmology journal Controlled trial quality: uncertain